Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market Elanco to Participate in Upcoming Investor Conferences Elanco Animal Health Reports First Quarter 2026 Results /C O R R E C T I O N -- Elanco Animal Health/ Pharmakonzern: Eli Lilly übernimmt Krebsspezialisten Ajax für bis zu 2,3 Milliarden Dollar Elanco Confirms Date and Conference Call for First Quarter 2026 Financial Results Announcement Elanco Launches Advantage™ Collar for Dogs with Four Months of Continuous Protection from Fleas, Ticks and Mosquitoes* Eli Lilly profitiert von neuer Abnehmpille Foundayo Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results Elanco to Participate in Upcoming Investor Conferences Elanco Announces Updates to Board of Directors Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs